REG - Scancell Hlds - Scancell Appoints Head of Business Development

Scancell HoldingsAnnouncement

07/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG6383La&default-theme=true

RNS Number : 6383L  Scancell Holdings Plc  07 September 2023

7 September 2023

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Appoints Dr Mandeep Sehmi as Head of Business Development

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces the
appointment of Dr Mandeep Sehmi as Head of Business Development, effective
immediately.

 

Mandeep Sehmi brings more than 10 years of experience in business development
and has previously held roles at leading UK biotech companies including at
Abcam, where she managed and developed the cancer and metabolism portfolios,
Cancer Research Technology, focussing on antibody out licensing, and
Isogenica, where she was involved in deals for their antibody platform,
including a multi-target deal with BioNTech. Mandeep joins Scancell from
ImaginAb where she held the role of Director of Business Development and
worked on a number of out-licensing opportunities for their lead asset with
biotech and pharma in Immuno-oncology for cell therapies, vaccines and
therapeutic antibodies. She holds a PhD in Cell and Molecular Biology and a
Master's degree in Molecular Pathology and Toxicology from the University of
Leicester, UK.

 

Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "The
appointment of Mandeep is an exciting development for Scancell as we continue
to expand our commercial capabilities. As communicated at the time of the
recent business update, our strategic focus is on the continued development of
the Company's two lead clinical assets SCIB1 and Modi-1. The value of our
antibody platform, however, remains a powerful asset in enabling us to
generate revenue through high value licence agreements and Mandeep, with her
extensive network and business development experience in the antibody sector,
will be invaluable as the Company continues to pursue attractive
commercialisation avenues for our therapeutic assets. We welcome Mandeep to
the team and look forward to working with her as we strive to bring innovative
medicines to patients while maximising value for our shareholders."

 

Dr Mandeep Sehmi, Head of Business Development at Scancell, added: "Scancell's
innovative cancer vaccines and antibodies have the potential to make a real
difference in the treatment of cancer. The commercial licence agreement signed
with Genmab, a leader in the field of antibody therapies for cancer, provides
strong validation of the potential of our proprietary antibody platform and I
am looking forward to joining the team to realise the commercial potential of
these therapies for the benefit of patients."

 

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 

 Consilium Strategic Communications          +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCLFMBTMTMMTTJ